Contact
searchSearch
HMP Global

Pharmacy Learning Network

PharmLaw

PharmLaw
Iowa Attorney General Accuses Insulin Makers and PBMs of Deceptive Pricing Practices
02/03/2026
Juliet Gallagher
Iowa Attorney General Brenna Bird has filed a sweeping lawsuit against major insulin manufacturers and pharmacy benefit managers (PBMs), alleging a coordinated, years-long scheme to artificially inflate the prices of insulin and other...
Iowa Attorney General Brenna Bird has filed a sweeping lawsuit against major insulin manufacturers and pharmacy benefit managers (PBMs), alleging a coordinated, years-long scheme to artificially inflate the prices of insulin and other...
Iowa Attorney General Brenna...
02/03/2026
Pharmacy Learning Network
PharmLaw
PCMA Sues California Over SB 41, Challenging PBM Fiduciary Duties Under ERISA
01/27/2026
Juliet Gallagher
California’s most ambitious pharmacy benefit manager (PBM) reform effort has drawn an immediate legal challenge, as the Pharmaceutical Care Management Association (PCMA) filed a federal lawsuit contesting key provisions of Senate Bill 41 (SB...
California’s most ambitious pharmacy benefit manager (PBM) reform effort has drawn an immediate legal challenge, as the Pharmaceutical Care Management Association (PCMA) filed a federal lawsuit contesting key provisions of Senate Bill 41 (SB...
California’s most ambitious...
01/27/2026
Pharmacy Learning Network
PharmLaw
Compounding Pharmacy Sues Eli Lilly, Novo Nordisk Over Alleged GLP-1 Antitrust Violations
01/21/2026
Juliet Gallagher
An Arizona-based compounding pharmacy has filed an antitrust lawsuit accusing Eli Lilly and Novo Nordisk of unlawfully restricting competition in the market for GLP-1 medications, escalating a legal battle over compounded versions of...
An Arizona-based compounding pharmacy has filed an antitrust lawsuit accusing Eli Lilly and Novo Nordisk of unlawfully restricting competition in the market for GLP-1 medications, escalating a legal battle over compounded versions of...
An Arizona-based compounding...
01/21/2026
Pharmacy Learning Network
PharmLaw
Oregon AG Files $900M Lawsuit Alleging Insulin Price-Fixing Scheme Involving PBMs and Manufacturers
01/14/2026
Juliet Gallagher
Oregon Attorney General Dan Rayfield has filed a sweeping lawsuit against 3 of the nation’s largest insulin manufacturers and 3 major pharmacy benefit managers (PBMs), alleging a coordinated scheme to artificially inflate insulin prices at...
Oregon Attorney General Dan Rayfield has filed a sweeping lawsuit against 3 of the nation’s largest insulin manufacturers and 3 major pharmacy benefit managers (PBMs), alleging a coordinated scheme to artificially inflate insulin prices at...
Oregon Attorney General Dan...
01/14/2026
Pharmacy Learning Network
PharmLaw
Jefferson Health Alleges Insulin Rebate Scheme Between PBMs and Drugmakers
01/09/2026
Juliet Gallagher
A major nonprofit health system has filed a federal lawsuit accusing leading insulin manufacturers and pharmacy benefit managers (PBMs) of conspiring to inflate insulin prices through rebate-driven pricing practices that allegedly harm...
A major nonprofit health system has filed a federal lawsuit accusing leading insulin manufacturers and pharmacy benefit managers (PBMs) of conspiring to inflate insulin prices through rebate-driven pricing practices that allegedly harm...
A major nonprofit health system...
01/09/2026
Pharmacy Learning Network

FDA Recalls

News
Antacid Tablets Recalled Due to Failed Disintegration Specifications
01/29/2026
Hannah Musick
The US Food and Drug Administration (FDA) has issued a Class II recall for INON ACE Antacid Tablets due to failed disintegration specifications, which may reduce the product’s effectiveness in relieving indigestion and gas.
The US Food and Drug Administration (FDA) has issued a Class II recall for INON ACE Antacid Tablets due to failed disintegration specifications, which may reduce the product’s effectiveness in relieving indigestion and gas.
The US Food and Drug...
01/29/2026
Pharmacy Learning Network
News
Glycopyrrolate Oral Solution Recalled Due to Degradation Specification Failure
01/29/2026
Hannah Musick
A Class III recall has been issued for glycopyrrolate oral solution due to degradation/impurity specification failure.
A Class III recall has been issued for glycopyrrolate oral solution due to degradation/impurity specification failure.
A Class III recall has been...
01/29/2026
Pharmacy Learning Network
News
Icosapent Ethyl Capsules Under Class II Recall
01/29/2026
Hannah Musick
The US Food and Drug Administration (FDA) is monitoring a Class II recall of icosapent ethyl capsules after capsule leakage caused subpotency, potentially affecting cardiovascular risk reduction therapy in patients with elevated triglycerides.
The US Food and Drug Administration (FDA) is monitoring a Class II recall of icosapent ethyl capsules after capsule leakage caused subpotency, potentially affecting cardiovascular risk reduction therapy in patients with elevated triglycerides.
The US Food and Drug...
01/29/2026
Pharmacy Learning Network
News
Recall Issued for Diclofenac Sodium Topical Gel Due to pH Specification Failure
01/22/2026
Grace Taylor, MS, MA
The US Food and Drug Administration (FDA) is overseeing a nationwide, voluntary Class III recall of diclofenac sodium topical gel 1% after the product failed to meet pH specifications, affecting more than 92 000 tubes distributed across the...
The US Food and Drug Administration (FDA) is overseeing a nationwide, voluntary Class III recall of diclofenac sodium topical gel 1% after the product failed to meet pH specifications, affecting more than 92 000 tubes distributed across the...
The US Food and Drug...
01/22/2026
Pharmacy Learning Network
News
FDA Reports Class II Recall of Subpotent Thyroid USP Bulk Drug Distributed Nationwide
01/22/2026
Grace Taylor, MS, MA
A voluntary Class II recall is underway for a bulk thyroid USP drug product after testing showed it was subpotent, raising concerns for manufacturers and pharmacists relying on accurate thyroid hormone strength.
A voluntary Class II recall is underway for a bulk thyroid USP drug product after testing showed it was subpotent, raising concerns for manufacturers and pharmacists relying on accurate thyroid hormone strength.
A voluntary Class II recall is...
01/22/2026
Pharmacy Learning Network

In the News

PharmLaw
Iowa Attorney General Accuses Insulin Makers and PBMs of Deceptive Pricing Practices
02/03/2026
Juliet Gallagher
Iowa Attorney General Brenna Bird has filed a sweeping lawsuit against major insulin manufacturers and pharmacy benefit managers (PBMs), alleging a coordinated, years-long scheme to artificially inflate the prices of insulin and other...
Iowa Attorney General Brenna Bird has filed a sweeping lawsuit against major insulin manufacturers and pharmacy benefit managers (PBMs), alleging a coordinated, years-long scheme to artificially inflate the prices of insulin and other...
Iowa Attorney General Brenna...
02/03/2026
Pharmacy Learning Network
News
Antacid Tablets Recalled Due to Failed Disintegration Specifications
01/29/2026
Hannah Musick
The US Food and Drug Administration (FDA) has issued a Class II recall for INON ACE Antacid Tablets due to failed disintegration specifications, which may reduce the product’s effectiveness in relieving indigestion and gas.
The US Food and Drug Administration (FDA) has issued a Class II recall for INON ACE Antacid Tablets due to failed disintegration specifications, which may reduce the product’s effectiveness in relieving indigestion and gas.
The US Food and Drug...
01/29/2026
Pharmacy Learning Network
News
Glycopyrrolate Oral Solution Recalled Due to Degradation Specification Failure
01/29/2026
Hannah Musick
A Class III recall has been issued for glycopyrrolate oral solution due to degradation/impurity specification failure.
A Class III recall has been issued for glycopyrrolate oral solution due to degradation/impurity specification failure.
A Class III recall has been...
01/29/2026
Pharmacy Learning Network
News
Icosapent Ethyl Capsules Under Class II Recall
01/29/2026
Hannah Musick
The US Food and Drug Administration (FDA) is monitoring a Class II recall of icosapent ethyl capsules after capsule leakage caused subpotency, potentially affecting cardiovascular risk reduction therapy in patients with elevated triglycerides.
The US Food and Drug Administration (FDA) is monitoring a Class II recall of icosapent ethyl capsules after capsule leakage caused subpotency, potentially affecting cardiovascular risk reduction therapy in patients with elevated triglycerides.
The US Food and Drug...
01/29/2026
Pharmacy Learning Network
PharmLaw
PCMA Sues California Over SB 41, Challenging PBM Fiduciary Duties Under ERISA
01/27/2026
Juliet Gallagher
California’s most ambitious pharmacy benefit manager (PBM) reform effort has drawn an immediate legal challenge, as the Pharmaceutical Care Management Association (PCMA) filed a federal lawsuit contesting key provisions of Senate Bill 41 (SB...
California’s most ambitious pharmacy benefit manager (PBM) reform effort has drawn an immediate legal challenge, as the Pharmaceutical Care Management Association (PCMA) filed a federal lawsuit contesting key provisions of Senate Bill 41 (SB...
California’s most ambitious...
01/27/2026
Pharmacy Learning Network

Subscribe Today

Pharmacy Learning Network Newsletter

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use